Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement
View original at globenewswire.comAlvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement REYKJAVIK, Iceland , June 16, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimi…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Total gross proceeds from the Offering and concurrent private placement are expected to be approximately $152 million, or approximately $165 million if underwriters exercise their full option.
60% confidenceThe public offering is expected to close on or about June 17, 2026, subject to customary closing conditions.
60% confidenceThe consummation of the Offering is not contingent on the consummation of the concurrent private placement.
60% confidenceThe Company expects to receive total gross proceeds of approximately $85 million from the Offering, or approximately $98 million if the underwriters exercise in full their option to purchase additional shares.
60% confidenceFive biosimilars are already approved and marketed in multiple global markets, including biosimilars to Humira, Stelara, Simponi, Eylea, and Prolia/Xgeva.
60% confidenceAlvotech intends to use net proceeds to fund continued development of biosimilar assets, working capital, general corporate purposes including IP protection, commercial expenditures, capital expenditures, acquisitions, pre-clinical and clinical development, R&D, pre-commercialization activities, and repayment or refinancing of indebtedness.
60% confidenceThe concurrent private placement is expected to close on or about June 25, 2026, subject to the consummation of the Offering and other customary conditions.
60% confidenceAlvotech's current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer.
60% confidenceGross proceeds from the concurrent private placement are expected to be approximately $67 million before deducting transaction-related expenses.
60% confidenceAlvotech seeks to be a global leader in biosimilars by delivering high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities.
60% confidence